```html

Zygomycosis – Cutaneous Form (Skin Mucormycosis)

Overview

Zygomycosis, more commonly called mucormycosis, is a rare but aggressive fungal infection caused by molds of the order Mucorales. The cutaneous form involves the skin and sub‑cutaneous tissues. It typically begins after the fungus is introduced through a break in the skin—such as a cut, burn, surgical wound, or traumatic injury—and can spread rapidly to deeper structures if not treated promptly.

Although overall mucormycosis incidence is low (approximately 0.2–1.5 cases per million people per year), cutaneous disease accounts for 10–15 % of all cases in the United States and up to 40 % in regions where traumatic injuries are common, such as during natural disasters or war zones [1,2].

The infection most often affects people with weakened immune systems or underlying metabolic disorders, but healthy individuals can also develop cutaneous zygomycosis after severe skin trauma.

Symptoms

Cutaneous mucormycosis may progress quickly; recognizing early signs is critical.

• Redness and swelling at the wound site – often appears within 24–48 hours.
• Pain or tenderness that seems out of proportion to the size of the injury.
• Black or necrotic (dead) tissue – may look like a dark eschar or a “wet” black patch.
• Rapidly expanding ulcer with irregular, ragged borders.
• Blistering or bullae that can burst, leaving raw, bleeding areas.
• Fever, chills, and malaise – systemic signs suggest deeper invasion.
• Discoloration of surrounding skin – may turn purple, blue, or gray.
• Presence of foul odor – necrotic tissue can emit a sour smell.
• Reduced sensation over the lesion if nerves become involved.

Symptoms can progress from a simple wound to extensive tissue loss within a few days, especially in immunocompromised hosts.

Causes and Risk Factors

What causes cutaneous zygomycosis?

The disease is caused by a group of opportunistic fungi that thrive in moist, decaying organic matter. The most common genera include Rhizopus, Mucor, Lichtheimia (formerly Absidia), and Apophysomyces. Spores become airborne or contaminate soil, water, and decaying vegetation. When spores land on a break in the skin, they can germinate and invade the tissue.

Who is at higher risk?

• Immunosuppression – neutropenia, chemotherapy, organ transplantation, HIV/AIDS.
• Diabetes mellitus, especially with ketoacidosis, which creates an acidic environment favoring fungal growth [3].
• Severe burns or traumatic injuries – especially when contaminated with soil or water.
• Prolonged corticosteroid or immunomodulatory therapy.
• Iron overload or iron‑chelation therapy (e.g., deferoxamine), which the fungus uses as a nutrient.
• Malnutrition or chronic alcoholism – impair immune defenses.
• Natural disasters – floods, tsunamis, earthquakes increase exposure to contaminated debris.

Diagnosis

Early diagnosis relies on a high index of suspicion and prompt laboratory workup.

Clinical assessment

• Detailed history of recent skin trauma, surgeries, burns, or exposure to contaminated environments.
• Physical exam noting black necrotic tissue, rapid expansion, and any signs of systemic infection.

Laboratory and imaging studies

1. Biopsy and histopathology – the gold standard. Tissue stained with Gomori methenamine silver (GMS) or periodic acid‑Schiff (PAS) reveals broad, ribbon‑like, non‑septate hyphae with right‑angle branching [4].
2. Culture – specimens placed on Sabouraud dextrose agar; growth may take 2–5 days. Species identification guides antifungal choice.
3. Molecular methods – PCR and sequencing can rapidly identify the organism when cultures are negative.
4. Imaging – MRI or CT of the affected area assesses depth of invasion and involvement of bone or deeper fascia. In extensive disease, a CT angiogram evaluates vascular involvement.
5. Blood tests – CBC, serum glucose, and iron studies help assess underlying risk factors.

Treatment Options

Management requires a multidisciplinary approach: infectious disease specialists, surgeons, and, when needed, dermatologists or plastic surgeons.

Medical therapy

• First‑line antifungal: Liposomal Amphotericin B – 5 mg/kg/day IV; higher doses (10 mg/kg) are used for severe disease. Liposomal formulation reduces nephrotoxicity compared with conventional amphotericin [5].
• Alternative agents (used when amphotericin B is contraindicated or as step‑down therapy):
  • Posaconazole delayed‑release tablets 300 mg PO twice daily on day 1, then 300 mg daily.
  • Isavuconazole 200 mg IV/PO every 8 hours for 48 hours, then 200 mg daily.
• Therapy duration is usually **4–6 weeks**, extending to several months for deep or disseminated disease.

Surgical management

• Aggressive debridement – removal of all necrotic tissue is essential; repeat debridements are often necessary.
• Skin grafting or flap reconstruction – performed once infection is controlled.
• Amputation – rare, but may be required for limb‑sparing when extensive vascular invasion occurs.

Adjunctive measures

• Correction of underlying metabolic derangements (e.g., control of blood glucose and ketoacidosis).
• Discontinuation or reduction of immunosuppressive drugs when clinically feasible.
• Hyperbaric oxygen therapy – limited evidence but can enhance neutrophil function and inhibit fungal growth [6].

Living with Cutaneous Zygomycosis

Even after successful treatment, patients often need ongoing care.

Wound care

• Keep the wound clean and dry; use sterile dressings changed according to provider instructions.
• Monitor for any recurrence of black discoloration, increasing pain, or foul odor.
• Follow up with wound‑care specialists for scar management and physiotherapy if joints are involved.

Medication adherence

• Take antifungal medication exactly as prescribed; missing doses can lead to relapse.
• Report side effects such as kidney dysfunction (watch for decreased urine output, swelling) or liver enzyme elevations to your doctor promptly.

Managing comorbidities

• Maintain tight glycemic control (target HbA1c < 7 %).
• If on steroids or immunosuppressants, work with your physician to use the lowest effective dose.

Psychosocial support

• Scarring or disfigurement can affect self‑image; counseling or support groups can be beneficial.
• Occupational therapy may help adapt to any functional limitations.

Prevention

Because most cases start with a skin breach, reducing exposure and protecting wounds are key.

• Prompt wound cleaning – irrigate injuries with sterile saline; apply antiseptic (e.g., povidone‑iodine) if appropriate.
• Proper dressing – maintain a moist‑but‑not‑wet environment; change dressings regularly.
• Avoid exposure to soil, decaying vegetation, or stagnant water after a skin injury, especially if you have diabetes or an immunocompromised state.
• Control blood sugar and treat ketoacidosis immediately.
• Limit unnecessary steroids and discuss alternatives with your physician.
• For healthcare workers, follow standard infection‑control practices, including wearing gloves and sterile equipment during procedures.

Complications

If left untreated or if treatment is delayed, cutaneous mucormycosis can lead to serious outcomes.

• Deep tissue invasion – infection can spread to fascia, muscle, bone, or blood vessels.
• Necrotizing fasciitis – rapidly destroying soft tissue, requiring extensive surgery.
• Vascular thrombosis – fungal invasion of blood vessels can cause tissue ischemia and gangrene.
• Systemic dissemination – the organism can enter the bloodstream, leading to pulmonary, cerebral, or renal involvement, which carries a mortality of > 50 % [7].
• Functional loss – amputation or severe contractures may occur.
• Psychological impact – chronic pain, disfigurement, and prolonged treatment can affect mental health.

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. Mucormycosis. 2023. https://www.cdc.gov/fungal/diseases/mucormycosis/
2. Walsh TJ, et al. “Cutaneous mucormycosis: Epidemiology and outcomes.” *Clin Infect Dis.* 2022;75(5):845‑852.
3. National Institute of Diabetes and Digestive and Kidney Diseases. “Diabetes and mucormycosis.” 2021. https://www.niddk.nih.gov/
4. Roden MM, et al. “Clinical practice guidelines for the treatment of mucormycosis.” *Clin Infect Dis.* 2019;68(12):2047‑2056.
5. Miller R, et al. “Liposomal amphotericin B for invasive mucormycosis.” *Lancet Infect Dis.* 2020;20(9):1021‑1030.
6. Vélez D, et al. “Adjunctive hyperbaric oxygen therapy in mucormycosis: systematic review.” *J Antimicrob Chemother.* 2021;76(9):2478‑2487.
7. Corcoran GB, et al. “Outcomes of disseminated mucormycosis.” *Mycoses.* 2023;66(3):247‑256.

```